Friday, May 03, 2024
QIAGEN has introduced QCI Secondary Analysis, a cloud-based software-as-a-service (SaaS) solution that facilitates high-throughput secondary analysis for clinical next-generation sequencing (NGS) data. This platform seamlessly integrates with QCI Interpret, QIAGEN's clinical variant interpretation and reporting software, and supports all QIAGEN QIAseq panels.
Traditionally, sequencing data goes through three phases: primary analysis, secondary analysis, and tertiary analysis. QCI Secondary Analysis focuses on the secondary analysis stage, where DNA fragments are assembled and analyzed for variants in relation to a reference genome. This tool simplifies the bioinformatics pipeline, making NGS testing more accessible to labs of varying sizes and expertise levels.
The platform is designed to streamline analysis from various assay types, minimizing resource investment while maximizing productivity. It is deployed on the secure QIAGEN Clinical Cloud, ensuring data protection and compliance with regulatory standards such as ISO 27001, GDPR, and HIPAA.
QCI Secondary Analysis complements QIAGEN's Sample to Insight portfolio, providing validated support for QIAseq panels, integration with QCI Interpret, and compatibility with other QIAGEN software modules like LightSpeed Clinical. QIAGEN Digital Insights solutions empower researchers and clinicians worldwide, facilitating data processing and interpretation for improved research outcomes.
For labs interested in leveraging comprehensive genomic information, QCI Secondary Analysis offers a user-friendly, turnkey solution. With its ability to process more sequencing data efficiently, this platform represents a significant advancement in precision medicine accessibility.
Source: qiagen.com
